111 related articles for article (PubMed ID: 2703390)
1. Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin.
Laurent F; Canal P; Soula G
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1101-3. PubMed ID: 2703390
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.
el Gamoussi R; Threadgill MD; Prade M; Stratford IJ; Guichard M
Cancer Chemother Pharmacol; 1993; 31(4):277-82. PubMed ID: 8422690
[TBL] [Abstract][Full Text] [Related]
3. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508.
Lespinasse F; Thomas C; Bonnay M; Malaise EP; Guichard M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1105-9. PubMed ID: 2522920
[TBL] [Abstract][Full Text] [Related]
4. Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.
Workman P; Newman HF; Bleehen NM; Ward R; Smithen CE
Cancer Chemother Pharmacol; 1991; 28(2):118-22. PubMed ID: 2060082
[TBL] [Abstract][Full Text] [Related]
5. The uptake of the radiosensitizing compound Ro 03-8799 (Pimonidazole) in human tumors.
Dische S; Bennett MH; Orchard R; Stratford MR; Wardman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1089-92. PubMed ID: 2703388
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of boron concentration on melanoma-bearing hamsters after administration of p-, m-, o-boronophenylalanine.
Hiratsuka J; Yoshino K; Kondoh H; Imajo Y; Mishima Y
Jpn J Cancer Res; 2000 Apr; 91(4):446-50. PubMed ID: 10804294
[TBL] [Abstract][Full Text] [Related]
7. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
Walton MI; Bleehen NM; Workman P
Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
10. Interaction of methotrexate with melanins and melanosomes from B16 melanoma.
Wilczok T; Stepień K; Buszman E; Porebska-Budny M
Biophys Chem; 1990 Apr; 35(2-3):265-70. PubMed ID: 2118811
[TBL] [Abstract][Full Text] [Related]
11. Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.
Walton MI; Bleehen NM; Workman P
Br J Cancer; 1989 May; 59(5):667-73. PubMed ID: 2736198
[TBL] [Abstract][Full Text] [Related]
12. Thiourea as a melanoma targeting agent.
Mårs U; Larsson BS
Melanoma Res; 1996 Apr; 6(2):113-20. PubMed ID: 8791268
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographic distribution of [14C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice.
Laurent F; Benard P; Canal P; Soula G
Cancer Chemother Pharmacol; 1988; 22(4):308-15. PubMed ID: 3168144
[TBL] [Abstract][Full Text] [Related]
14. Suitable indices for evaluating the intensity of tumor metastasis in a mouse experimental metastatic model.
Yoshikawa N; Nakamura K; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
In Vivo; 2001; 15(6):485-8. PubMed ID: 11887333
[TBL] [Abstract][Full Text] [Related]
15. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences.
Guerquin-Kern JL; Hillion F; Madelmont JC; Labarre P; Papon J; Croisy A
Biomed Eng Online; 2004 Apr; 3():10. PubMed ID: 15068483
[TBL] [Abstract][Full Text] [Related]
16. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
17. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
Cobb LM; Nolan J; Butler SA
Br J Cancer; 1990 Dec; 62(6):915-8. PubMed ID: 2257219
[TBL] [Abstract][Full Text] [Related]
18. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
Awwad HK; el Badawy S; abd el Baki H; Zaghloul M; el Moneim Osman A; Akoush H; Fairchild K
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1083-4. PubMed ID: 2522918
[TBL] [Abstract][Full Text] [Related]
20. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
